ABVC BioPharma, Inc.: 10-K filed 2015-04-16

Name: ABVC BioPharma, Inc.: 10-K filed 2015-04-16
Creator: ABVC BioPharma, Inc.

What ABVC BioPharma, Inc. reported in its annual report filed 2015-04-16 (fiscal FY 2013): 26 published measures, 54 facts as tagged in accession 0001557234-15-000092.

This filing

Form: 10-K (annual report)
Filed: 2015-04-16
Fiscal period: fiscal FY 2013
Accession: 0001557234-15-000092 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ABVC BioPharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-09-30	231,969	USD
At 2012-09-30	302,308	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-09-30	-1,880,174	USD
At 2012-09-30	-1,643,778	USD
At 2011-09-30	-1,463,673	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-09-30	618	USD
At 2012-09-30	13,386	USD
At 2011-09-30	71,784	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	-226,352	USD	365
2011-10-01 to 2012-09-30	-1,069,579	USD	366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	-37,768	USD	365
2011-10-01 to 2012-09-30	-915,124	USD	366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	0	USD	365
2011-10-01 to 2012-09-30	350	USD	366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	7,787	USD	365
2011-10-01 to 2012-09-30	5,714	USD	366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	25,000	USD	365
2011-10-01 to 2012-09-30	876,272	USD	366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	0	USD	365
2011-10-01 to 2012-09-30	-19,546	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-09-30	-30,550,258	USD
At 2012-09-30	-30,313,862	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	0	USD	365
2011-10-01 to 2012-09-30	67,637	USD	366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-09-30	37,249	USD
At 2012-09-30	46,783	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	-177,259	USD	365
2011-10-01 to 2012-09-30	-1,143,046	USD	366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-09-30	1,856	USD
At 2012-09-30	48,336	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	49,093	USD	365
2011-10-01 to 2012-09-30	87,698	USD	366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-09-30	2,112,143	USD
At 2012-09-30	1,946,086	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2013-09-30	192,864	USD
At 2012-09-30	207,189	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2013-09-30	1,238	USD
At 2012-09-30	0	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	185,046	USD	365
2011-10-01 to 2012-09-30	1,148,760	USD	366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-09-30	54,593,032	shares
At 2012-09-30	14,158,506	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-09-30	28,615,490	USD
At 2012-09-30	28,615,490	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2013-09-30	0	USD
At 2012-09-30	0	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	-236,396	USD	365
2011-10-01 to 2012-09-30	-1,539,443	USD	366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	-49,093	USD	365
2011-10-01 to 2012-09-30	141,104	USD	366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	1,238	USD	365
2011-10-01 to 2012-09-30	0	USD	366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-10-01 to 2013-09-30	81,920	USD	365
2011-10-01 to 2012-09-30	-192,157	USD	366

Inspect the source

Entity: ABVC BioPharma, Inc. / CIK 0001173313
Captured: 2026-09-19T11:16:49.109Z
SEC response SHA-256: a42942c118304cb578665c27ca73d827a17f370dd57a31742c919c9b41b25c34

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001173313.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))